MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Ataxia: Treatment"

  • 2025 International Congress

    Ataxia in PBC: The Overlooked Role of Fat-Soluble Vitamin Deficiency

    M. Rajani, P. Prakash (Providence, USA)

    Objective: To describe the investigation of ataxia in a patient with primary biliary cholangitis (PBC) despite ursodeoxycholic acid (UDCA) treatment. Background: PBC is an autoimmune…
  • 2025 International Congress

    A Clinical Overlap Presentation of Episodic Ataxia Type 2 and Periodic Paralysis with a Novel Mutation in CACNA1A

    C. Vila, K. Minks, P. Morrison (Rochester, USA)

    Objective: To describe a case of episodic ataxia type 2 (EA2) with features of periodic paralysis (PP) associated with a novel mutation in CACNA1A. Background:…
  • 2025 International Congress

    Effectiveness of Intensive Speech Treatment for Friedreich’s Ataxia

    L. Ramig, H. Hodges, E. Peterson, M. Tran, A. Lowit (Tucson, USA)

    Objective: ​​​​​​1. Test feasibility of providing online intensive speech treatment to people with Friedreich’s Ataxia (FA)2. Compare benefits of two treatment targets (vocal loudness-LSVT LOUD;…
  • 2025 International Congress

    Pleozymes, A Multifunctional Nanozyme for Targeting Metabolic Deficits in Friedreich’s Ataxia

    U. Khan, K. Mouli, A. Liopo, P. Derry, T. Kent (Houston, USA)

    Objective: Mitochondrial dysfunction in Friedreich’s Ataxia (FRDA) results from GAA repeat expansion in the FXN gene, reducing frataxin levels thus disrupting iron-sulfur clusters essential for…
  • 2025 International Congress

    A 37 years-old man with Epilepsy and Progressive Autoimmune Ataxia

    J. Balderas Juárez, A. Zepeda Rodríguez, R. Padilla García (Mexico City, Mexico)

    Objective: Describe a young patient with medial past history of Epilepsy who started with progressive symptoms of imbalance, vertigo, nausea, oscillopsy and recurrence of seizures.…
  • 2025 International Congress

    Effects of an Intensive Multidisciplinary Rehabilitation Program on Patients with Spinocerebellar Ataxia

    F. Coimbra, MC. da Cunha, J. Veloso, M. da Cunha, MR. Moreno, E. Mosimann, L. Siciliani, JR. Junior, J. Caetano, CE. Del Rio, C. Couto (Rio de Janeiro, Brazil)

    Objective: To evaluate the effectiveness of an intensive multidisciplinary rehabilitation program in patients with spinocerebellar ataxia. Background: Spinocerebellar ataxias (SCAs) cause significant motor impairment, affecting…
  • 2025 International Congress

    A Case Report of Two Affected Siblings with Spinocerebellar Ataxia Type 1

    S. Fu, U. Agarwal, I. Goldszer (Detroit, USA)

    Objective: To present a case of two affected siblings with Spinocerebellar ataxia type 1 Background: Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative…
  • 2025 International Congress

    Spinocerebellar Ataxia Type 40 (SCA-40) with a Novel Mutation in an Indian Female: A Case Report

    A. Mehta, P. Hiremath, M. Javali, P. R, L. Priya, P. Acharya (Bengaluru, India)

    Objective: To report the first Indian patient with SCA 40 who presented in the fifth decade with a novel missense mutation (c.1291C>T, p.His431Tyr), expanding the…
  • 2025 International Congress

    Beyond the Classic Triad: An Unusual Phenomenology of Parkinsonism in a Patient with Superficial Siderosis (SS)

    D. Sblendorio, J. Frey (Morgantown, USA)

    Objective: To highlight the phenomenology in a complex case of superficial siderosis (SS) presenting with hearing loss, ataxia, and parkinsonism Background: SS is a rare…
  • 2025 International Congress

    Long-Term Effectiveness and Tolerability of Vatiquinone in an Adult Friedreich’s Ataxia Population

    C. Werner, S. Perlman, J. Blaize, M. Rance, J. Cherry, O. Zhang, L. Golden, D. Lynch, T. Zesiewicz (Frankfurt, Germany)

    Objective: To assess the long-term effect of vatiquinone (EPI-743) on disease progression in adults with Friedreich’s ataxia (FA) from Study 006, compared with a matched…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley